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Triple-negative breast cancer (TNBC), especially the subset with a basal phenotype, represents the most aggres-
sive subtype of breast cancer. Unlike other solid tumors, TNBCs harbor a low number of driver mutations. Con-
versely, we and others have demonstrated a significant impact of epigenetic alterations, including DNA
methylation and histone post-translational modifications, affecting TNBCs. Due to the promising results in pre-
clinical studies, histone deacetylase inhibitors (HDACi) are currently being tested in several clinical trials for
breast cancer and other solid tumors. However, the genome-wide epigenetic and transcriptomic implications
of HDAC inhibition are still poorly understood. Here, we provide detailed information about the design of a
multi-platform dataset that describes the epigenomic and transcriptomic effects of HDACi. This dataset includes
genome-wide chromatin accessibility (assessed by ATAC-Sequencing), DNA methylation (assessed by Illumina
HM450K BeadChip) and gene expression (assessed by RNA-Sequencing) analyses before and after HDACi treat-
ment of HCC1806 and MDA-MB-231, two human TNBC cell lines with basal-like phenotype.
© 2017 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Specifications
Organism/cell
line/tissue
Homo sapiens/cancer cell lines (HCC1806 and MDA-MB-231)
Sex Female
Sequencer or
array type
- Illumina HiSeq 2500
- Illumina HumanMethylation450 BeadChip
Data format Raw (FASTQ) and analyzed (BigWig) for ATAC sequencing data
Raw (FASTQ) and analyzed (TXT) for RNA sequencing data
Raw (IDAT) and analyzed (TXT) for DNA methylation arrays data
Experimental
factors
Human triple-negative cell lines treated with HDAC inhibitor
(LBH589)
Experimental
features
HCC1806 and MDA-MB-231 treated with 10 nM of LBH589 for
28 days
Consent N/A
Sample source
location
N/A
1. Direct link to deposited data
Study SuperSeries (GSE92911) Access:
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=
mlodeuqanxslvmz&acc=GSE92911
ATAC-Sequencing SubSeries (GSE92898) Access: https://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?token=qjudwycgtfsfnuv&acc=
GSE92898
RNA-Sequencing SubSeries (GSE92910) Access:
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=
svsnwcgivzudfif&acc=GSE92910
DNA methylation SubSeries (GSE92909) Access:
https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=
grgxqoouphyjhmz&acc=GSE92909
2. Experimental design and cell culture conditions
HCC1806 (cat#CRL-2335; ATCC, Manassas, VA) and MDA-MB-231
(cat#HTB-26; ATCC, Manassas, VA) cells were cultured in RPMI 1640
supplemented with 10 mM HEPES, 10% heat-inactivated fetal bovine
serum (FBS) and 1% penicillin-streptomycin (complete medium)
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containing 10 nM of LBH589 (Panobinostat; cat#S1030; Selleck
Chemicals, Houston, TX) during 120 h followed by 48 h of incubation
in RPMI-1640 medium alone. To maintain the drug concentration, the
medium was refreshed every 24 h. This cycle was repeated 4 times to
complete 28 days of treatment. In parallel, HCC1806 and MDA-MB-
231 cells were cultured in complete medium containing drug vehicle
(DMSO) alone for the same period of time (28 days). RNA-Sequencing
(RNA-Seq), Assay for Transposase-Accessible Chromatin Sequencing
(ATAC-Seq), andDNAmethylation arrayswereperformedafter the 4 cy-
cles. Finally, to evaluate the stability of HDACi-induced epigenetic
reprogramming, HCC1806 and MDA-MB-231 treated during 28 days
with 10 nM of LBH589 were cultured in complete medium alone for
14 additional days, and ATAC-Seq was performed. Gene expression
and DNA methylation profiling were also performed after the initial
96 h of incubation to evaluate early response to 10 nM of LBH589. A de-
scription of the cell lines analyzed, the regimens used and the data anal-
yses performed are summarized in Table 1.
3. Assay for Transposase-accessible chromatin sequencing (ATAC-Seq)
ATAC-Seq was performed as previously described by Buenrostro
et al. [1]. Briefly, 50,000 cells were washed in 50 μl cold PBS and
resuspended in 50 μl cold lysis buffer [1]. The nuclei were centrifuged
at 500 x g for 10 min at 4 °C. The pellet was then incubated with
transposition reaction mix for 30 min at 37 °C and then purified
using the MinElute PCR Purification kit (Qiagen, Hilden, Germany).
The eluted transposed DNA was barcoded and amplified for 5 cycles,
and then 5 μl of the product was used for a qPCR side-reaction to
prevent amplification saturation. The optimal amount of additional
PCR cycles was determined based on the number of cycles that rep-
resented one-third of maximum fluorescence intensity in the qPCR
reaction after 20 cycles. The final transposed DNA was amplified for
a total of 9–11 cycles. The final amplified library was purified using
MinElute PCR Purification kit and eluted in 20ul elution buffer. The
ATAC libraries were sequenced on the Illumina HiSeq 2500 in Rapid
Mode using 50 bp paired-end at the John Wayne Cancer Institute
(JWCI) Sequencing Center.
4. ATAC-Seq data processing
Raw genomic sequence reads were mapped to the 1000 Genomes
(b37) build of the human genome reference using BWA-MEM (version
0.7.5a) with default settings [2]. Alignments were further processed
using GATK (version 2.8–1) [3] for INDEL realignment and PicardTools
for duplicate marking (version 1.103) (http://broadinstitute.github.io/
picard/). ATAC-Seq peaks were identified using the callpeaks function
in MACS2 [4] with a threshold set to -q = 0.01. The resulting peak
calls were filtered for sequences that mapped to the mitochondria
using shell scripts, and BigWig files were generated using
bedGraphToBigWig [5].
5. RNA sequencing (RNA-Seq)
Total RNA from HCC1806 and MDA-MB-231 cells was extracted
using ZR-Duet DNA/RNA MiniPrep Plus (cat# D7003; Zymo Research,
Irvine, CA). RNA samples with high quality (RIN ≥ 8.0) and high purity
(OD 260/280 = 1.8–2.0) scores were used to generate libraries using
the Illumina TruSeq RNA Sample Preparation Kit v2 (Illumina Inc., San
Diego, CA). The mRNA libraries were sequenced on the Illumina HiSeq
2500 in Rapid Mode using 101 bp paired-end reads at the JWCI Se-
quencing Center [6].
6. RNA-Seq data processing
Base calling and de-multiplexingwere processed using CASAVA v1.8
(Illumina Inc., San Diego, CA), reads were mapped to the GENCODE re-
lease 19 reference using STAR version 2.4.2a [7], and read counts were
generated using the –quantMode GeneCounts option in STAR. The
Bioconductor package DESeq2 was used to detect fold change differ-
ences in expression between conditions.
7. DNA methylation profiling (HM450K)
Genomic DNA was extracted from HCC1806 andMDA-MB-231 cells
using the Quick-gDNA MiniPrep kit (cat# D3025; Zymo Research,
Irvine, CA). Following, 1 μg of DNA was sodium bisulfite modified
(SBM) using the EZ DNA Methylation-Direct kit (cat# D5021; Zymo
Research, Irvine, CA). 200 ng of SBM-DNA was whole-genome
amplified, enzymatically fragmented and hybridized on the
HumanMethylation450 (HM450K) BeadChip (Illumina Inc., San Diego,
CA). The chips were scanned with Illumina iScan (Illumina, Inc., San
Diego, CA), as we previously described [8–11].
8. DNA methylation data processing
Data was extracted using the R packagemethylumi. The ‘noob’ func-
tion in the R package minfi was used to process the data and then the
‘dasen’ function in the R package wateRmelon for normalization and
dye-bias correction. DNA methylation levels were reported as β-value
(β= intensity of the methylated allele/(intensity of the unmethylated
allele+ intensity of themethylated allele)) and calculated using the sig-
nal intensity value for each CpG site.
9. Discussion
In this article, we described a dataset involving transcriptomic and
epigenomic analysis of TNBC cells that were exposed for a prolonged
time to low doses of a clinically-approved HDACi. While the functional
consequences of this treatment approach remains to be elucidated in
the future, this multi-platform evaluation provides an opportunity to
deeply understand the genome-wide effects of this powerful epigenetic
drug and to identify novel transcriptomic and epigenomic clinically-rel-
evant targets for TNBC tumors.
Table 1
Summary of the data analyses included in the dataset.
Name Treatment ATAC-Seq HM450K RNA-Seq
HCC1806-DMSO-96hs DMSO for 96 h x x ✓
HCC1806-LB-96hs LBH589 (10 nM) for 96 h x ✓ ✓
HCC1806-DMSO-4w DMSO for 28 days ✓ ✓ ✓
HCC1806-LB-4w LBH589 (10 nM) for 28 days ✓ ✓ ✓
HCC1806-LB-4w + complete medium-2w LBH589 (10 nM) for 28 days + complete medium for 14 days ✓ x x
MDA-MB-231-DMSO-96hs DMSO for 96 h x x ✓
MDA-MB-231-LB-96hs LBH589 (10 nM) for 96 h x ✓ ✓
MDA-MB-231-DMSO-4w DMSO for 28 days ✓ ✓ ✓
MDA-MB-231-LB-4w LBH589 (10 nM) for 28 days ✓ ✓ ✓
MDA-MB-231-LB-4w + complete medium-2w LBH589 (10 nM) for 28 days + complete medium for 14 days ✓ x x
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